Safety database in OnePV
Every ICSR, from book-in to E2B(R3)
The pharmacovigilance safety database at the centre of OnePV: ICSR processing, MedDRA and WHODrug coding, narratives, quality and medical review, with a full audit trail.
- 10+years in the industry
- 300+clients
- 55+inspections behind us
A sample case record, US-EXAMPLE-0522, drawn as seven stacked sections of the ICH E2B(R3) message. C.1, identification of the case safety report: Day 0 is 3 November 2026. C.2.r, primary source: a physician in the United States. C.3, sender: Northbridge Pharma. D, patient: female, 54 years. E.i, reaction: anaphylactic reaction, MedDRA lowest level term and preferred term 10002198. G.k, drug: Exampril 10 mg tablets, suspect. H, narrative: drafted by Gen AI, reviewed and signed by the safety physician.
Trusted by 300+ clients, including
Anatomy of a case record
Each case is one record, in the sections ICH E2B(R3) defines. Book-in, coding, review, signature and submission all land on that one record.
-
C.1 Identification of the case safety report
E2B(R3) is built from this same record and submitted to FDA, EMA, MHRA and Health Canada.
-
C.1.4 Date first received
Day 0: the first receipt of the four minimum criteria; the reporting clock runs from here.
3 Nov 2026 · Day 0
-
C.2.r Primary source(s) of information
Physician, United States
-
C.3 Information on sender
Northbridge Pharma
-
D Patient characteristics
Female, 54 years
-
E.i Reaction(s) / event(s)
Coded in MedDRA.
Reported as “anaphylactic reaction” LLT and PT 10002198 SOC Immune system disorders Seriousness (E.i.3.2): caused or prolonged hospitalisation
-
G.k Drug(s) information
Coded in WHODrug.
Exampril 10 mg tablets G.k.1 characterisation of drug role: suspect
-
G.k.9.i.2.r Relatedness of drug to reaction(s) / event(s)
The reporter’s and the company’s assessments are kept separately; the company’s is recorded at medical review.
Reporter: related Company: assessed at medical review
-
H.1 Case narrative
Gen AI drafts it; a safety physician reviews it and signs.
-
Across the record
Every field change versioned and attributable, with e-signature where required.
Sample data from case US-EXAMPLE-0522; Exampril and Northbridge Pharma are fictional. Serious and unexpected, so the 15-day report is due 18 Nov 2026. Expectedness is the company’s assessment against the reference safety information; ICH E2B(R3) has no data element for it, so it carries no ID here.
From information to submission
The work on a case
Each step lands on the same case record, in configurable workflows. Your case processors and safety physicians check what Gen AI extracts and approve what it drafts.
-
Book-in
Day 0: the first receipt of the four minimum criteria.
3 Nov 2026 Day 0
-
Triage
Seriousness and expectedness set the reporting clock.
Serious, unexpected Due 18 Nov 2026
-
Data entry
Gen AI extracts the fields from the source; the case processor checks each one.
-
Coding
MedDRA for the reaction, WHODrug for the drug.
LLT/PT 10002198 Exampril 10 mg tablets
-
Quality review
A reviewer checks the case for completeness and accuracy before medical review.
-
Medical review
A safety physician assesses causality and records the company assessment.
Reporter: related Company: recorded here
-
Approval
E-signature, with the signer, the date and time, and its meaning.
-
Submission
E2B(R3) built from the record.
To FDA Sent on day 2 of 15
Sample data from case US-EXAMPLE-0522. Exampril is fictional.
At the centre of OnePV
Case intake and literature management feed the safety database. E2B(R3) submissions are built from it, and signal detection and PV agreements work from the same data.
Case intake
Email, web forms, call centre (MICC) and partner reports in one triage queue.
Literature management
PubMed and Embase; relevant articles become cases inside the safety workflow.
Safety database
ICSR processing, coding and medical review
E2B(R3) submission
- FDA
- EMA
- MHRA
- Health Canada
Signal detection
PRR, ROR and EBGM, with a recorded decision for every signal.
PV agreements (SDEA)
Safety data exchange agreements, working from the same data.
One system for patients, medical devices, cosmetics and veterinary medicines. Veterinary Safety runs on the same safety database.
Compliance and validation
IQ/OQ/PQ validation is part of every engagement, not a paid add-on.
IQInstallation
qualificationOQOperational
qualificationPQPerformance
qualification
| Standard | How the safety database meets it |
|---|---|
| 21 CFR Part 11 | Built for. Every field change is versioned and attributable, with e-signature where required. |
| EU Annex 11 | Built for computerised systems in GxP use, with a full audit trail. |
| GxP and GAMP 5 | Built for. IQ/OQ/PQ validation included in every engagement. |
| ICH E2B(R3) | Submission to FDA, EMA, MHRA and Health Canada, built from the case record. |
| GDPR and HIPAA | Built for. |
| ISO 9001 and ISO 27001 | Clinevo is certified for quality management and information security. |
| SOC 2 Type II | Clinevo is independently audited for security, with its controls tested over a period of operation. |
Moving from your current safety database
Four steps from discovery to live submissions, with your historical cases moved across and your team trained by role.
Discovery and scoping
Your products, case volumes, reporting obligations, partners and current system.
Configuration and validation
Workflows, reporting rules and roles configured, then validated with IQ/OQ/PQ.
Data migration and training
Historical cases moved from your current safety database; role-based training for case processors, physicians and administrators.
Go-live and support
Live submissions, with 24/7 support.
What a Head of Drug Safety says
“With Clinevo Safety, we have transformed our adverse event reporting process. Submitting over 10,000 cases annually to the USFDA and EMA has never been smoother.”
- 10+years in the industry
- 300+clients
- 55+inspections behind us